8-K: Biogen Reports Mixed 2023 Results, Projects Return to EPS Growth in 2024

Biogen's 2023 results show a mixed performance with revenue declines but the company anticipates a return to non-GAAP EPS growth in 2024.

Summary

• Biogen reported its fourth quarter and full year 2023 financial results, showing a decrease in total revenue for both periods.
• Fourth quarter revenue was $2.4 billion, a 6% decrease compared to the same period in 2022, while full year revenue was $9.8 billion, a 3% decrease year-over-year.
• GAAP diluted EPS for the fourth quarter was $1.71 and non-GAAP diluted EPS was $2.95, both negatively impacted by $0.35 related to ADUHELM closeout costs.
• Full year GAAP diluted EPS was $7.97 and non-GAAP diluted EPS was $14.72.
• The company expects a return to non-GAAP EPS growth in 2024, with a guidance range of $15.00 to $16.00, representing approximately 5% growth at the mid-point.
• Total revenue is expected to decline by a lowto mid-single digit percentage in 2024, but core pharmaceutical revenue is expected to be flat.
• Biogen anticipates operating income to grow by a low-double digit percentage in 2024, with a mid-single digit percentage point operating margin expansion.
• The 'Fit for Growth' program is expected to generate $1 billion in gross savings and $800 million net savings by 2025, with approximately $200 million already achieved.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with revenue declines and cost-cutting measures, but also positive developments in new product launches and a projected return to EPS growth. The sentiment is neutral to slightly negative due to the current financial performance.

Positives

• Biogen expects a return to non-GAAP EPS growth in 2024, with a projected 5% increase at the mid-point.
• The 'Fit for Growth' program is on track to deliver significant cost savings, with $200 million already achieved.
• New product launches, including SKYCLARYS and ZURZUVAE, are showing promising early results.
• LEQEMBI's approval in China and co-promotion efforts in the U.S. and Japan are positive developments.
• Operating income is expected to grow by a low-double digit percentage in 2024.

Negatives

• Total revenue decreased by 6% in the fourth quarter of 2023 and 3% for the full year compared to 2022.
• GAAP and non-GAAP diluted EPS were negatively impacted by $0.35 due to ADUHELM closeout costs.
• Total revenue is expected to decline by a lowto mid-single digit percentage in 2024.
• Multiple sclerosis product revenue declined by 14% for the full year 2023.
• Contract manufacturing revenue is expected to be significantly lower in 2024 compared to 2023.

Risks

• The company is dependent on sales from its products, and faces significant product competition.
• There is uncertainty in developing, licensing, or acquiring new product candidates.
• The company faces risks related to healthcare reforms and commercialization of biosimilars.
• There are risks associated with clinical trials, including unexpected concerns and regulatory delays.
• The company faces risks related to technology failures, manufacturing processes, and international business operations.
• Fluctuations in operating results and changes in tax rates could impact financial performance.
• The company has a net debt of approximately $5.9 billion.

Future Outlook

Biogen expects a return to non-GAAP EPS growth in 2024, with a guidance range of $15.00 to $16.00. Total revenue is expected to decline by a lowto mid-single digit percentage, while core pharmaceutical revenue is expected to be flat. Operating income is expected to grow by a low-double digit percentage.

Management Comments

• 2023 was a year of transformation for Biogen as we saw approval for four first-in-class medicines while we realigned our cost structure, remained prudent in allocating shareholder capital, and reprioritized our pipeline.
• We believe with these key elements in place we are now well positioned to return Biogen to sustainable growth.
• As we look to 2024, our focus is on operational execution, including building upon the progress of our recent new product launches.
• We believe this will allow us to continue to advance our goal of a new Biogen that creates enhanced value for patients and our shareholders.

Industry Context

Biogen's results reflect the challenges faced by many large pharmaceutical companies, including patent expirations and increased competition. The focus on new product launches and cost-cutting measures is a common strategy in the industry to drive future growth. The co-promotion of LEQEMBI and expansion into rare diseases are also in line with industry trends.

Comparison to Industry Standards

• Biogen's revenue decline is similar to other large pharmaceutical companies facing patent expirations and increased competition from generics and biosimilars, such as Teva and Viatris.
• The company's focus on cost-cutting through the 'Fit for Growth' program is a common strategy, similar to restructuring efforts seen at companies like Sanofi and Novartis.
• The launch of new products like SKYCLARYS and ZURZUVAE is crucial for Biogen's future growth, mirroring the strategies of companies like Vertex Pharmaceuticals that focus on innovative therapies.
• The co-promotion of LEQEMBI is a strategic move similar to partnerships seen in the industry, such as the collaboration between Pfizer and BioNTech for their COVID-19 vaccine.
• Biogen's net debt of $5.9 billion is a significant figure, and it will be important to monitor how the company manages this debt compared to peers like AbbVie and Bristol Myers Squibb.

Stakeholder Impact

• Shareholders may be concerned about the revenue decline but encouraged by the projected EPS growth and cost-saving initiatives.
• Employees may be affected by the 'Fit for Growth' program, which includes restructuring and cost-saving measures.
• Patients may benefit from the new product launches, such as SKYCLARYS and ZURZUVAE.
• Suppliers and creditors may be impacted by the company's cost-cutting measures and financial performance.

Next Steps

• Biogen will focus on operational execution and building upon the progress of recent new product launches in 2024.
• The company will continue to implement the 'Fit for Growth' program to achieve cost savings.
• Biogen will continue to co-promote LEQEMBI in the U.S. and Japan.
• The company will monitor the performance of new products like SKYCLARYS and ZURZUVAE.

Key Dates

Keywords

Biogen, Financial Results, EPS Growth, Revenue Decline, Pharmaceuticals, LEQEMBI, SKYCLARYS, ZURZUVAE, Fit for Growth, Cost Savings, Multiple Sclerosis, Rare Disease, Biosimilars